Skip to content

OSC Co-culture for Rescue IVM of Human GV Oocytes

Effect of iPSC-Derived Ovarian Support Cell Co-culture on Rescue In Vitro Maturation of Human Germinal Vesicle Oocytes: A Randomized Sibling-Oocyte Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07559357
Acronym
OSC-rIVM
Enrollment
102
Registered
2026-04-30
Start date
2026-06-01
Completion date
2027-05-01
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Oocyte Maturation

Keywords

Rescue in vitro maturation, r-IVM, Germinal vesicle oocyte, iPSC-derived ovarian support cells, OSC co-culture, Embryo development, IVF, Sibling-oocyte trial

Brief summary

This single-center randomized sibling-oocyte controlled trial evaluates whether co-culture with induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) improves rescue in vitro maturation (r-IVM) outcomes of surplus germinal vesicle (GV) oocytes collected during routine IVF treatment. Eligible GV oocytes from each enrolled participant are allocated within participant in a 1:1 ratio to either conventional r-IVM or r-IVM with OSC co-culture. The primary outcome is the metaphase II (MII) maturation rate after 24 hours of culture. Secondary outcomes include fertilization rate, day 3 embryo formation, good-quality day 3 embryo rate, blastocyst formation, and good-quality blastocyst rate. All embryos generated in the study are for research purposes only and will not be used for clinical embryo transfer.

Detailed description

Immature human oocytes at the germinal vesicle (GV) stage retrieved during routine IVF cycles are usually not used in standard clinical treatment. Rescue in vitro maturation (r-IVM) offers a potential strategy to increase the number of mature oocytes available for laboratory use, but maturation outcomes for GV oocytes remain limited. This study investigates whether co-culture with iPSC-derived ovarian support cells (OSCs) can improve the biological performance of r-IVM in surplus GV oocytes. This is a single-center, randomized, sibling-oocyte controlled study conducted at the Infertility Department of Hung Vuong Hospital, Ho Chi Minh City, Vietnam. Women undergoing routine IVF who have at least two eligible GV oocytes in one retrieval cycle may participate after providing informed consent. Within each participant, eligible GV oocytes are allocated in a 1:1 ratio to either conventional r-IVM in CSCMC medium or r-IVM in CSCMC medium with iPSC-derived OSC co-culture. Allocation is performed separately within each participant using a manual lottery-based randomization procedure. If an odd number of eligible GV oocytes is available, one oocyte is randomly excluded before allocation to preserve equal within-participant assignment. Oocytes in both groups are cultured under identical laboratory conditions; the only difference between groups is the presence of OSCs in the intervention arm. Matured oocytes are assessed after 24 hours. Oocytes reaching MII undergo ICSI, and fertilized oocytes are cultured to day 5-6 in a time-lapse system. Embryo development is evaluated using standard morphology criteria with independent assessment and time-lapse support. The study is designed to compare biological outcomes between conventional r-IVM and OSC-supported r-IVM while minimizing between-patient confounding through within-participant allocation. The participant is treated as the clustering unit for statistical analysis. This section is taken from the protocol's rationale, procedures, randomization logic, and outcome plan.

Interventions

OTHERConventional rescue in vitro maturation

Standard rescue in vitro maturation of denuded germinal vesicle oocytes in CSCMC culture medium for 24 hours under routine IVF laboratory conditions.

OTHERRescue in vitro maturation with iPSC-derived ovarian support cell co-culture

Rescue in vitro maturation of denuded germinal vesicle oocytes in CSCMC culture medium for 24 hours with co-culture using iPSC-derived ovarian support cells supplied by Dioseve Inc. and prepared according to the laboratory SOP.

Sponsors

Hung Vuong Hospital
Lead SponsorOTHER
Dioseve Inc.
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Masking description

Embryologists performing culture procedures cannot be blinded because the presence or absence of OSC co-culture is evident during laboratory handling. However, outcome assessment is performed independently by embryologists who are not involved in allocation and who assess recoded masked identifiers.

Intervention model description

Within each enrolled participant, eligible GV oocytes are allocated in a 1:1 ratio to conventional rescue in vitro maturation (r-IVM) or r-IVM with iPSC-derived ovarian support cell (OSC) co-culture. Allocation is performed separately within each participant using a manual lottery-based randomization procedure. When an odd number of eligible GV oocytes is available, one oocyte is randomly excluded before allocation to preserve equal within-participant assignment. The participant is treated as the clustering unit in statistical analyses.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Women aged 18 to 45 years. * At least 2 GV oocytes retrieved in a single oocyte retrieval cycle. * Voluntary informed consent from the couple to participate in the study. * Agreement that all embryos generated from the study will be used for research purposes only and will not be transferred for clinical treatment.

Exclusion criteria

* Sperm obtained through surgical retrieval procedures, including PESA, MESA, TESE, or micro-TESE. * Use of donor gametes, including donor oocytes or donor sperm. * Participants with GV oocytes showing obvious morphological abnormalities, such as degeneration, severe deformation, or marked cytoplasmic abnormalities.

Design outcomes

Primary

MeasureTime frameDescription
MII maturation rate after 24 hours of culture24 hours after initiation of cultureProportion of cultured GV oocytes that reach metaphase II (MII) after 24 hours of rescue in vitro maturation.

Secondary

MeasureTime frameDescription
Fertilization rate17 to 19 hours after ICSIProportion of injected oocytes showing normal fertilization with two pronuclei (2PN).
Day 3 embryo formation rateDay 3 after fertilizationProportion of normally fertilized oocytes that develop to cleavage-stage embryos by day 3.
Good-quality day 3 embryo rateDay 3 after fertilizationProportion of day 3 embryos meeting predefined good-quality criteria.
Blastocyst formation rateDay 5 to Day 6 after fertilizationProportion of normally fertilized oocytes that develop to the blastocyst stage by day 5 or day 6.
Good-quality blastocyst rateDay 5 to Day 6 after fertilizationProportion of blastocysts meeting predefined good-quality criteria.

Countries

Vietnam

Contacts

CONTACTHuy Phuong Tran, PhD
tranphuonghuy1994@gmail.com+84 896 416 098
PRINCIPAL_INVESTIGATORTuyet Thi-Diem Hoang, MD

Hung Vuong Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026